Priovant Therapeutics Announces Receipt of Fast Track Designation from FDA for Brepocitinib in Non-Anterior Non-Infectious Uveitis (NIU) & Start of Enrollment of Brepocitinib Phase 3 NIU Program

First patients have been dosed in CLARITY, a Phase 3 study evaluating brepocitinib in non-anterior non-infectious uveitis (NIU). Brepocitinib has also been granted Fast Track Designation from FDA for NIU. Study initiation follows successful Phase 2 study of brepocitinib in NIU (NEPTUNE)…